June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Effects of inhibition of neovascular signalling in a model of retinopathy of prematurity
Author Affiliations & Notes
  • Peter Heiduschka
    Research laboratory, Department of Ophthalmology, University of Muenster Medical Centre, Muenster, Germany
  • Tanja Plagemann
    Research laboratory, Department of Ophthalmology, University of Muenster Medical Centre, Muenster, Germany
  • Anne F. Alex
    Department of Ophthalmology, University of Muenster Medical Centre, Muenster, Germany
  • Nicole Eter
    Department of Ophthalmology, University of Muenster Medical Centre, Muenster, Germany
  • Footnotes
    Commercial Relationships   Peter Heiduschka, Bayer (F); Tanja Plagemann, None; Anne Alex, None; Nicole Eter, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3459. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Peter Heiduschka, Tanja Plagemann, Anne F. Alex, Nicole Eter; Effects of inhibition of neovascular signalling in a model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3459.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinopathy of prematurity (ROP) can be treated by blocking of VEGF. In a mouse model of ROP, we tested if blocking of placental growth factor (PlGF) would result in effects comparable to those achieved by anti-VEGF treatment. We also tested combined blocking of VEGF and PlGF and effects of Sunitinib that blocks many pro-angiogenic pathways.

Methods : C57BL/6 mice were exposed to 75% oxygen from postnatal days P7 to P12. After return to ambient air, intravitreal injections were performed. In three control groups, PBS or two neutral IgG molecules were injected. Mice of a fourth control group remained untouched after O2 treatment. In the treatment groups, antibodies against VEGF or PlGF, a mixture of anti-VEGF and anti-PlGF, and Sunitinib were injected. At least 10 eyes were evaluated in each group. On P17, electroretinographic (ERG) measurements were performed. The eyes were isolated, and blood vessels in retinal whole mounts were stained to evaluate avascular zones and neovascularisation. Results are expressed as percent of total retinal area with standard deviation (SD). Statistical analysis was done using the Kruskal-Wallis test.

Results : Eyes of control groups showed similar neovascularisation (1.7-3.4%, SD 0.8-1.3%). Neovascularisation was clearly less (0.6-0.9%, SD 0.4-0.6%) in all treatment groups compared to controls (p<0.01 for antibodies and p<0.05 for sunitinib). Avascular zones in the retinas of all control groups showed similar values (15.6-22.7%, SD 4.6-8.8%). In eyes injected with anti-VEGF, avascular zones were reduced down to 4.0±2.7% (p<0.001 for control groups), but they were not reduced significantly when anti-PlGF, anti-VEGF+anti-PlGF or Sunitinib were injected (13.6-21.2%, SD 4.4-6.2%).
ERG measurements did not reveal significant differences between the controls and the treatment groups. Amplitudes of a-waves were slightly larger in treated mice than in controls, and b-waves and amplitudes of oscillatory potentials were slightly larger in anti-VEGF treated mice than in all other groups.

Conclusions : Blocking of PlGF or injection of sunitinib results in a similar inhibition of neovascularisation as by anti-VEGF treatment in the mouse model of ROP. However, physiological angiogenesis that occurs after anti-VEGF treatment is blocked by anti-PlGF or sunitinib treatment. This indicates that pathological neovascularisation follows different pathways than physiological angiogenesis in ROP.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×